Jerini’s Firazyr For HAE Gets Advisory Committee Review Feb. 20
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee is slated to review icatibant for hereditary angioedema.